Aug 12, 2026
Pipeline
TScan is developing a robust pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer.
Title
Indications
Targets
HLA type
Discovery/Preclinical
IND-enabling
Phase I
Pivotal
Engineered TCR-T Cell Therapies
Swipe left to show more
Hematologic Malignancies
AML, MDS
TSC-101
(HA-2)
(HA-2)
HLA-A*02:01
Hematologic Malignancies
AML, MDS
TSC-102
(CD45)
(CD45)
HLA-A*03:01
HLA-A*01:01
HLA-A*24:02
Title
Indications
Targets
HLA type
Discovery/ Preclinical
IND-enabling
Phase 1
Pivotal
Column
Engineered TCR-T Cell Therapies
Swipe left to show more
Hematologic Malignancies
AML, MDS
TSC-101
(HA-2)
(HA-2)
HLA-A*02:01
Hematologic Malignancies
Hematologic Malignancies
AML, MDS
TSC-102
(CD45)
(CD45)
HLA-A*03:01
Hematologic Malignancies
HLA-A*01:01
HLA-A*24:02
Engineered TCR-T Cell Therapies
Swipe left to show more
Solid Tumors
In vivo-engineered TCR-Ts
Target-directed therapeutics
Swipe left to show more
Autoimmunity
Systemic sclerosis, Ulcerative Colitis,
Ankylosing Spondylitis, Birdshot uveitis
Ankylosing Spondylitis, Birdshot uveitis
Autoimmunity
Crohn's
Expanded Access Policy
TScan Therapeutics is focused on the development and potential commercialization of novel therapies to treat hematologic and oncologic malignancies, as well as other diseases.
At this time, TScan does not provide access to investigational products outside of clinical trials. We encourage patients to participate in clinical trials of our investigational therapies whenever possible, because clinical trials are designed, conducted, and monitored to ensure that the safety and efficacy are appropriately evaluated before they are submitted to regulatory agencies for review with the intent to make them more broadly available to patients.
You and your health care provider may learn more about our clinical trials by visiting www.clinicaltrials.gov and searching for TScan.
If you are a health care provider who is interested in learning more about one of our investigational therapies, or a physician with questions about participation in one of our clinical trials, please submit a request to medicalaffairs@tscan.com. The Company will acknowledge questions as soon as possible, usually within 5 business days of receipt.
TScan Therapeutics reserves the right to revise this expanded access policy at any time.